A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies (NCT06528301)
A Phase 1, Multicenter, Open-label Study of UB-VV111 in Combination With Rapamycin in Relapsed/Refractory (R/R) CD19+ B-cell Malignancies
🩺 Plain-English Summary (8th-Grade Level)
This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- City of Hope — Duarte, California
- The David and Etta Jonas Center for Cellular Therapy — Chicago, Illinois
- Washington University School of Medicine/Siteman Cancer Center — St Louis, Missouri
- University of Nebraska Medical Center — Omaha, Nebraska
- University of Cincinnatti Medical Center — Cincinnatti, Ohio
- Fred Hutch Cancer Center — Seattle, Washington
- Royal North Shore Hospital — Saint Leonards, New South Wales
- St. Vincent's Hospital Melbourne — Fitzroy, Victoria
📞 Contact the Study Coordinator
Phone: (206) 227-5056
Email: luke.walker@umoja-biopharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lymphoma, B-Cell
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) — Scottsdale, Arizona
- FT819 in Subjects With B-cell Malignancies — Birmingham, Alabama
- Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma — Vancouver, British Columbia
- Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. — Burbank, California
- Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma — Birmingham, Alabama
- Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers — New York, New York
Explore by condition: All Lymphoma, B-Cell clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.